ClinicalTrials.gg
CompletedNCT01988012Updated Mar 6, 2017Results posted

A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.

A Phase 3 interventional study of tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 13 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
53rd of 110
100 · median 97
Started
2014
with 8 others
Phase 3
65 of 110
none open now
Registered
77th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 53rd largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 77th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

A multi-center, open-label single-arm study to evaluate the efficacy and safety of tocilizumab administered as a single, weekly injection in adults with rheumatoid arthritis. Combination therapy with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) was permitted.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults >/= 18 years of age
  • Diagnosis of active rheumatoid arthritis (RA) according to the revised (1987) American College of Rheumatology (ACR) criteria or European League Against Rheumatism (EULAR)/ACR (2010) criteria
  • Previously treated with the following: three non-biologic DMARDs, and not treated with any biologic agent OR one biologic agent (alone or in combination with non-biologic DMARDs), and discontinued that agent for a reason
  • Oral (\</= 10 mg/day prednisone or equivalent), non-steroidal anti-inflammatory drug (NSAIDs) and non-biologic DMARDs are permitted if on a stable dose regimen for >/= 4 weeks prior to Baseline
  • Use of effective throughout the study as defined by protocol; female patients of must not be pregnant

Exclusion criteria

Exclusion Criteria:

  • Presence of serious, uncontrolled, medical conditions
  • History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower gastrointestinal (GI) disease that might predispose to perforation
  • Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections
  • Any infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening
  • Clinically significant findings on lab tests and/or or C, or (HIV) screenings
  • Active tuberculosis (TB) requiring treatments within the previous 3 years
  • Evidence of active malignant disease, diagnosed within the previous 10 years, or breast cancer diagnosed within the previous 20 years
  • History of alcohol, drug, or chemical abuse within 1 year prior to Screening
  • Neuropathies or other conditions that might interfere with pain evaluation
  • Major surgery (including joint surgery) within 8 weeks prior to Screening or planned major surgery within 6 months following Baseline
  • Rheumatic disease other than RA, including systemic lupus erythematosus, mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's syndrome). Secondary Sjögren's syndrome with RA is permitted
  • Functional Class IV as defined by the ACR Classification of Functional Status in-Rheumatoid Arthritis
  • Diagnosis of juvenile idiopathic arthritis or juvenile RA, and/or RA before the age of 16
  • Prior history of current inflammatory joint disease other than RA
  • Exposure to tocilizumab (either IV or subcutaneous administration) at any time prior to Baseline
  • Treatment with any agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of Screening
  • Previous treatment with any cell-depleting therapies, including investigational agents approved therapies, with alkylating agents such as chlorambucil, or with total lymphoid irradiation
  • Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline
  • Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Adults with rheumatoid arthritis will be treated with tocilizumab for 24 weeks followed by an 8 week follow-up period without treatment.

    Biological: tocilizumab

Interventions

  • Biologicaltocilizumab

    162 milligram (mg) administered subcutaneously once weekly for 24 weeks

    Also known as: RoActemra/Actemra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission and CDAI Low Disease Activity

    Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. Remission is defined as CDAI ≤2.8 and Low Disease Activity (LDA) is defined as 2.8\< CDAI ≤10.

    Time frame: Week 24

  2. Change From Baseline in CDAI

    Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 24

  3. Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission and SDAI Low Disease Activity

    Simplified Disease Activity Index (SDAI) was an index for measuring disease activity in RA and had a good correlation with the DAS28. The index was calculated using the following formula: SDAI: SJC28 + TJC28 + PGA (10 cm VAS) + PhGA (10 cm VAS + C-Reactive Protein (CRP) in milligram/liter (mg/L). VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. An SDAI score of ≤ 3.3 represents clinical remission, a score of ≤ 11.0 represents low disease activity.

    Time frame: Week 24

  4. Change From Baseline in SDAI

    Simplified Disease Activity Index (SDAI) was an index for measuring disease activity in RA and had a good correlation with the DAS28. The index was calculated using the following formula: SDAI: SJC28 + TJC28 + PGA (10 cm VAS) + PhGA (10 cm VAS + C-Reactive Protein (CRP) in mg/L. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 24

  5. Change From Baseline in Disease Activity Score 28-Erythrocyte-Sedimentation Rate (DAS28-ESR)

    The DAS28-ESR score is a measure of the patient's disease activity calculated using the tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), patient's global assessment (PGA) of disease activity based on visual analog scale (VAS) and the erythrocyte sedimentation rate (ESR) in millimeter/hour (mm/hr). VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total possible score ranged from 0 to 10. Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 24

  6. Percentage of Participants Achieving 20%, 50% and 70% Improvement in American College of Rheumatology (ACR) Response Scores (ACR20, ACR50 and ACR70)

    An ACR20 response requires at least 20% improvement compared to baseline in SJC (based on 66 joints) and TJC (based on 68 joints) as well as at least 20% improvement in 3 of the following 5 assessments: 1) PGA pain VAS, 2) PGA VAS; 3) physician's global assessment of disease activity VAS, 4) Health Assessment Questionnaire-Disability Index (HAQ-DI) with 20 questions consisting of 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do; and 5) CRP in mg/L or ESR in mm/hr. ACR50 and ACR70 responses are defined in a similar way except that they required a 50% and 70% improvement from baseline, respectively. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity).

    Time frame: Week 24

  7. Percentage of Participants With Good to Moderate European League Against Rheumatism (EULAR) Response

    Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit. Participants with a score lesser than or equal to (\</=) 3.2 and reduction of greater than (\>) 1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score \<=5.1 with reduction of \>0.6 to \<=1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to \<=1.2 points, or any score with reduction \<=0.6 points, were assessed as non-responders with response recorded as 'none.'

    Time frame: Week 24

  8. Change From Baseline in TJC and SJC

    The number of tender joints (based on 68 joints) and swollen joints (based on 66 joints) were counted at each visit. TJC was determined by identifying the joints that were painful under pressure or to passive motion; no tenderness =0, tenderness =1. SJC was determined by identifying swelling; no swelling =0, swelling =1. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 24

  9. Change From Baseline in Percentage of Participants on Tocilizumab Monotherapy

    Participants were either on tocilizumab monotherapy or tocilizumab plus non-biologic disease modifying anti-rheumatic drugs (DMARDs). Reported here is the percentage of participants on tocilizumab monotherapy at baseline and the change from baseline at Week 24. A positive change from baseline at Week 24 indicates the percentage of participants, who discontinued DMARDs during the study.

    Time frame: Baseline, Week 24

  10. Change From Baseline in Patient Global Assessment of Disease Activity Visual Analog Scale (PGA VAS)

    PGA VAS represents the participant's overall assessment of their current disease activity on a 100 millimeter (mm) horizontal VAS scale from 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 24

  11. Change From Baseline in Patient Pain VAS

    Patient Pain VAS represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS scale from 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 24

  12. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)

    The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities and 20 questions. Each category contains multiple questions, which were answered using a 4-point scale from 0 (without any difficulty) to 3 (unable to do). The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 24

  13. Change From Baseline in Patient Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)

    The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 52. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. A positive change from baseline indicates an improvement.

    Time frame: Baseline, Week 24

  14. Total Scores on Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Scale (HAS)

    The HDRS is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 54. A higher score indicates a worse outcome. HAS is a clinician-administered assessment to measure the severity of anxiety symptoms and consists of 14 items with a total score range from 0 to 56. A higher score indicates a worse outcome.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest (AESIs)

    An AE is any untoward medical occurrence in a participant administered a drug and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug, whether or not considered related to the drug. Preexisting conditions which worsen during a study are also considered as AEs. AESIs are AEs that occur in categories of special interest with regard to the benefit-risk profile and overall safety of a drug. The following nine categories of AESIs were identified for tocilizumab: 1) serious and/or medically significant infections, 2) myocardial infarction/acute coronary syndrome, 3) gastrointestinal perforations, 4) malignancies, 5) anaphylaxis/hypersensitivity reactions, 6) demyelinating disorders, 7) stroke, 8) serious and/or medically significant bleeding events, and 9) serious and/or medically significant hepatic events.

    Time frame: Up to Follow-up Week 32

  2. Percentage of Participants Who Required Dose Modifications or Discontinued Study Due to AEs

    Time frame: Up to Week 24

  3. Immunogenicity: Percentage of Participants With Anti-tocilizumab Antibodies

    Reported is the percentage of participants positive for anti-tocilizumab antibodies in the confirmatory anti-tocilizumab antibody assay, which followed an initial anti-tocilizumab screen. Participants, who withdrew from the study

    Time frame: Baseline, Week 24, Follow-up Week 32 and Early Withdrawal

  4. Immunogenicity: Tocilizumab Levels

    Time frame: Week 12, Week 24, Follow-up Week 32 and Early Withdrawal

  5. Immunogenicity: Change From Week 1 in Soluble Interleukin-6 Receptor (sIL-6R) Levels

    A positive change from Week 1 indicates an increase in sIL-6R levels.

    Time frame: Week 1, Week 12, Week 24, Follow-up Week 32 and Early Withdrawal

07

Results

Posted Mar 6, 2017

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab
Started100
Completed85
Not completed15
Withdrew: Adverse event5
Withdrew: Insufficient therapeutic response3
Withdrew: Patient withdrawal of consent4
Withdrew: Lost to follow-up1
Withdrew: Physician decision1
Withdrew: Protocol violation1

Outcome measures

PrimaryPercentage of Participants With Clinical Disease Activity Index (CDAI) Remission and CDAI Low Disease Activity

Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. Remission is defined as CDAI ≤2.8 and Low Disease Activity (LDA) is defined as 2.8\< CDAI ≤10.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission and CDAI Low Disease Activity
percentage of participantsTocilizumab
CDAI Remission16.5
CDAI LDA34.1
PrimaryChange From Baseline in CDAI

Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in CDAI
units on a scaleTocilizumab
Baseline31.89 ± 14.35
Change from Baseline at Week 24-18.29 ± 14.52
PrimaryPercentage of Participants With Simplified Disease Activity Index (SDAI) Remission and SDAI Low Disease Activity

Simplified Disease Activity Index (SDAI) was an index for measuring disease activity in RA and had a good correlation with the DAS28. The index was calculated using the following formula: SDAI: SJC28 + TJC28 + PGA (10 cm VAS) + PhGA (10 cm VAS + C-Reactive Protein (CRP) in milligram/liter (mg/L). VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. An SDAI score of ≤ 3.3 represents clinical remission, a score of ≤ 11.0 represents low disease activity.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission and SDAI Low Disease Activity
percentage of participantsTocilizumab
SDAI Remission19.2
SDAI LDA38.5
PrimaryChange From Baseline in SDAI

Simplified Disease Activity Index (SDAI) was an index for measuring disease activity in RA and had a good correlation with the DAS28. The index was calculated using the following formula: SDAI: SJC28 + TJC28 + PGA (10 cm VAS) + PhGA (10 cm VAS + C-Reactive Protein (CRP) in mg/L. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in SDAI
units on a scaleTocilizumab
Baseline33.73 ± 14.83
Change from Baseline at Week 24-21.41 ± 14.99
PrimaryChange From Baseline in Disease Activity Score 28-Erythrocyte-Sedimentation Rate (DAS28-ESR)

The DAS28-ESR score is a measure of the patient's disease activity calculated using the tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), patient's global assessment (PGA) of disease activity based on visual analog scale (VAS) and the erythrocyte sedimentation rate (ESR) in millimeter/hour (mm/hr). VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total possible score ranged from 0 to 10. Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score 28-Erythrocyte-Sedimentation Rate (DAS28-ESR)
units on a scaleTocilizumab
Baseline4.98 ± 0.98
Change from Baseline at Week 24-2.47 ± 1.29
PrimaryPercentage of Participants Achieving 20%, 50% and 70% Improvement in American College of Rheumatology (ACR) Response Scores (ACR20, ACR50 and ACR70)

An ACR20 response requires at least 20% improvement compared to baseline in SJC (based on 66 joints) and TJC (based on 68 joints) as well as at least 20% improvement in 3 of the following 5 assessments: 1) PGA pain VAS, 2) PGA VAS; 3) physician's global assessment of disease activity VAS, 4) Health Assessment Questionnaire-Disability Index (HAQ-DI) with 20 questions consisting of 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do; and 5) CRP in mg/L or ESR in mm/hr. ACR50 and ACR70 responses are defined in a similar way except that they required a 50% and 70% improvement from baseline, respectively. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 20%, 50% and 70% Improvement in American College of Rheumatology (ACR) Response Scores (ACR20, ACR50 and ACR70)
percentage of participantsTocilizumab
ACR2062.4
ACR5037.6
ACR7020.0
PrimaryPercentage of Participants With Good to Moderate European League Against Rheumatism (EULAR) Response

Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit. Participants with a score lesser than or equal to (\</=) 3.2 and reduction of greater than (\>) 1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score \<=5.1 with reduction of \>0.6 to \<=1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to \<=1.2 points, or any score with reduction \<=0.6 points, were assessed as non-responders with response recorded as 'none.'

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Good to Moderate European League Against Rheumatism (EULAR) Response
percentage of participantsTocilizumab
Percentage of Participants With Good to Moderate European League Against Rheumatism (EULAR) Response96.4
PrimaryChange From Baseline in TJC and SJC

The number of tender joints (based on 68 joints) and swollen joints (based on 66 joints) were counted at each visit. TJC was determined by identifying the joints that were painful under pressure or to passive motion; no tenderness =0, tenderness =1. SJC was determined by identifying swelling; no swelling =0, swelling =1. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · joint count
Change From Baseline in TJC and SJC
joint countTocilizumab
TJC at Baseline21.42 ± 15.20
TJC Change from Baseline at Week 24-11.91 ± 13.59
SJC at Baseline10.30 ± 10.27
SJC Change from Baseline at Week 24-7.54 ± 9.60
PrimaryChange From Baseline in Percentage of Participants on Tocilizumab Monotherapy

Participants were either on tocilizumab monotherapy or tocilizumab plus non-biologic disease modifying anti-rheumatic drugs (DMARDs). Reported here is the percentage of participants on tocilizumab monotherapy at baseline and the change from baseline at Week 24. A positive change from baseline at Week 24 indicates the percentage of participants, who discontinued DMARDs during the study.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Change From Baseline in Percentage of Participants on Tocilizumab Monotherapy
percentage of participantsTocilizumab
Baseline26
Change from Baseline at Week 2412
PrimaryChange From Baseline in Patient Global Assessment of Disease Activity Visual Analog Scale (PGA VAS)

PGA VAS represents the participant's overall assessment of their current disease activity on a 100 millimeter (mm) horizontal VAS scale from 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Patient Global Assessment of Disease Activity Visual Analog Scale (PGA VAS)
units on a scaleTocilizumab
Baseline69.73 ± 24.55
Change from Baseline at Week 24-31.22 ± 28.43
PrimaryChange From Baseline in Patient Pain VAS

Patient Pain VAS represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS scale from 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Patient Pain VAS
units on a scaleTocilizumab
Baseline64.82 ± 26.39
Change from Baseline at Week 24-29.11 ± 29.16
PrimaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)

The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities and 20 questions. Each category contains multiple questions, which were answered using a 4-point scale from 0 (without any difficulty) to 3 (unable to do). The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
units on a scaleTocilizumab
Baseline1.55 ± 0.80
Change from Baseline at Week 24-0.34 ± 0.62
PrimaryChange From Baseline in Patient Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)

The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 52. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. A positive change from baseline indicates an improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Patient Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)
units on a scaleTocilizumab
Baseline23.46 ± 11.32
Change from Baseline at Week 246.95 ± 9.70
PrimaryTotal Scores on Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Scale (HAS)

The HDRS is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 54. A higher score indicates a worse outcome. HAS is a clinician-administered assessment to measure the severity of anxiety symptoms and consists of 14 items with a total score range from 0 to 56. A higher score indicates a worse outcome.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Total Scores on Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Scale (HAS)
units on a scaleTocilizumab
HDRS at Baseline7.87 ± 7.19
HDRS at Week 244.94 ± 5.85
HAS at Baseline8.56 ± 8.43
HAS at Week 245.93 ± 7.17
SecondaryPercentage of Participants With Adverse Events (AEs) and AEs of Special Interest (AESIs)

An AE is any untoward medical occurrence in a participant administered a drug and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug, whether or not considered related to the drug. Preexisting conditions which worsen during a study are also considered as AEs. AESIs are AEs that occur in categories of special interest with regard to the benefit-risk profile and overall safety of a drug. The following nine categories of AESIs were identified for tocilizumab: 1) serious and/or medically significant infections, 2) myocardial infarction/acute coronary syndrome, 3) gastrointestinal perforations, 4) malignancies, 5) anaphylaxis/hypersensitivity reactions, 6) demyelinating disorders, 7) stroke, 8) serious and/or medically significant bleeding events, and 9) serious and/or medically significant hepatic events.

Time frame:
Up to Follow-up Week 32
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest (AESIs)
percentage of participantsTocilizumab
AEs70.0
AESIs7.0
SecondaryPercentage of Participants Who Required Dose Modifications or Discontinued Study Due to AEs
Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Dose Modifications or Discontinued Study Due to AEs
percentage of participantsTocilizumab
% of Particpants with Dose Modifications16
% of Participants Who Discontinued Study5
SecondaryImmunogenicity: Percentage of Participants With Anti-tocilizumab Antibodies

Reported is the percentage of participants positive for anti-tocilizumab antibodies in the confirmatory anti-tocilizumab antibody assay, which followed an initial anti-tocilizumab screen. Participants, who withdrew from the study

Time frame:
Baseline, Week 24, Follow-up Week 32 and Early Withdrawal
Reported as:
Number · percentage of participants
Immunogenicity: Percentage of Participants With Anti-tocilizumab Antibodies
percentage of participantsTocilizumab
Baseline1.0
Week 240
Follow-up Visit Week 320
Early Withdrawal0
SecondaryImmunogenicity: Tocilizumab Levels
Time frame:
Week 12, Week 24, Follow-up Week 32 and Early Withdrawal
Reported as:
Mean · microgram/milliliter (mcg/mL)
Immunogenicity: Tocilizumab Levels
microgram/milliliter (mcg/mL)Tocilizumab
Week 1235.49 ± 17.81
Week 2441.63 ± 22.79
Follow-up Week 3239.53 ± 28.47
Early withdrawal19.04 ± 15.69
SecondaryImmunogenicity: Change From Week 1 in Soluble Interleukin-6 Receptor (sIL-6R) Levels

A positive change from Week 1 indicates an increase in sIL-6R levels.

Time frame:
Week 1, Week 12, Week 24, Follow-up Week 32 and Early Withdrawal
Reported as:
Mean · nanograms/milliliter (ng/mL)
Immunogenicity: Change From Week 1 in Soluble Interleukin-6 Receptor (sIL-6R) Levels
nanograms/milliliter (ng/mL)Tocilizumab
Week 138.33 ± 10.30
Change from Week 1 at Week 12475.79 ± 120.98
Change from Week 1 at Week 24503.67 ± 127.13
Change from Week 1 at Follow-up at Week 32382.26 ± 240.95
Change from Week 1 at Early withdrawal309.91 ± 183.07

Adverse events

Collected over Up to Follow-up Week 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—6/100 (6%)44/100 (44%)
Most frequent serious events
Most frequent serious events
EventTocilizumab
ColitisGastrointestinal disorders1/100
Chest painGeneral disorders1/100
CellulitisInfections and infestations1/100
Adnexal torsionReproductive system and breast disorders1/100
UrticariaSkin and subcutaneous tissue disorders1/100
HaematomaVascular disorders1/100
Most frequent other events
Most frequent other events
EventTocilizumab
NeutropeniaBlood and lymphatic system disorders12/100
LeukopeniaBlood and lymphatic system disorders11/100
Hepatic enzyme increasedInvestigations11/100
Alanine aminotransferase increasedInvestigations8/100
Upper respiratory tract infectionInfections and infestations7/100
Urinary tract infectionInfections and infestations7/100
Aspartate aminotransferase increasedInvestigations6/100

Baseline characteristics

The full analysis set (FAS) included all enrolled participants who received at least one dose of subcutaneous tocilizumab.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean54.3 ± 11.8
Gender
Gender(Participants)Tocilizumab
Female80
Male20
08

Study locations

13 sites
  • Beer Sheva, 8410101, Israel
  • Beer Yaacov, 6093000, Israel
  • Haifa, 3109601, Israel
  • Haifa, 3339419, Israel
  • Haifa, 34362, Israel
  • Jerusalem, 9112001, Israel
  • Jerusalem, 91240, Israel
  • Kfar Saba, 44281, Israel
  • Petach Tikva, 4937211, Israel
  • Petach Tikva, 4941492, Israel
  • Ramat Gan, 5262000, Israel
  • Ramat Gan, 5262100, Israel
  • Tel Aviv, 6423906, Israel
09

References and documents

Publications

  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Petho-Schramm A. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. PubMed 30649524 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Petho-Schramm A. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum In: Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. PubMed 29244149 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2013
First posted
Nov 20, 2013
Start
Jan 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Mar 6, 2017
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01988012
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 20, 2013
Start date
Jan 2014
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Mar 6, 2017
Last update
Mar 6, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion